...
首页> 外文期刊>Physiological Research >Lost in Menopausal Transition: the Timing of Atherosclerosis Prevention in Women
【24h】

Lost in Menopausal Transition: the Timing of Atherosclerosis Prevention in Women

机译:失去更年期转变:女性动脉粥样硬化预防的时间

获取原文
获取原文并翻译 | 示例
           

摘要

Advanced atherosclerotic changes can often resist even to very aggressive treatment. Although basic mechanisms of its origin and development are known, some important steps in this process are still waiting for more detailed explanation. Therefore, in addition to already proved aggressive lowering of LDL cholesterol, appropriate timing of atherosclerosis treatment is of the essence. Revealing different stages of atherosclerotic process, less or more sensitive to treatment is of primary importance; however, its detection is complicated by several facts including not exactly identifiable periods of quiescence and progression of atherosclerotic process. One of populations, study of which could add valuable information regarding this problem, are women in menopausal transition. Previously unsuccessful therapy with hormone replacement therapy is restudied with focus on the time of/after menopause. Now, it is supposed to be favorable in women soon, approximately less than 8 years, after menopause. In addition, the same principle - optimal timing of the intervention of traditional cardiovascular risk factors, especially lipids, could be also of importance. Therefore, menopausal transition could be optimal period for the intervention in women at risk. However, this approach is to be proved by evidence from controlled prospective studies focused on lifestyle and/or pharmacological intervention.
机译:即使是非常积极的治疗,晚期动脉粥样硬化变化也往往会产生抵抗力。虽然其起源和发展的基本机制已为人所知,但这一过程中的一些重要步骤仍有待更详细的解释。因此,除了已经证实的积极降低低密度脂蛋白胆固醇外,适当的动脉粥样硬化治疗时机至关重要。揭示动脉粥样硬化过程的不同阶段,对治疗的敏感性降低或提高是最重要的;然而,它的检测由于几个因素而变得复杂,包括不能准确识别动脉粥样硬化过程的静止期和进展期。其中一个人群是处于更年期过渡期的女性,这项研究可以为这一问题提供有价值的信息。以往激素替代疗法不成功的治疗将重新研究,重点放在绝经时间/绝经后。现在,这对绝经后不久,大约不到8年的女性是有利的。此外,同样的原则——对传统心血管危险因素,尤其是脂质进行干预的最佳时机也很重要。因此,处于绝经风险期的女性进行干预可能是最佳的。然而,这一方法将被集中于生活方式和/或药物干预的对照前瞻性研究的证据所证明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号